Get started
Author

Clara Domke

Observed name: C. Domke
Observed institution: Molecular Partners (Switzerland)
ORCID: 0000-0002-4855-0824
Observed ORCID: 0000-0002-4855-0824
OpenAlex ID: A5069331726
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
2022 · Nicolò Rigamonti, Niina Veitonmäki, et al. · Cancer Immunology Research · 32
PDF
Abstract 1733: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo
2021 · Kyriaki Ioannou, Simone Ragusa, et al. · Cancer Research · 3
Abstract 339: Development of 212Pb-based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumors
2025 · Stephan Wullschleger, Amal Saidi, et al. · Cancer Research · 1
Data from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.
Data from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.
Supplementary Figure from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.
Supplementary Figure from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.
Works count: 9
Citation count: 36
H-index: 2
I10-index: 1
Year
Topic
Type